CLIENTRON-CORP.
15.10.2019 15:02:04 CEST | Business Wire | Press release
Clientron Corp., a leading global provider of Thin Client, POS and embedded systems, introduces the brand new all-in-one Thin Client TC238 that features a 23.8” display with fanless and ultra-slim enclosure, and system designed with the concept of Intel® Smart Display Module (Intel® SDM) for optimized display computing. The TC238 AiO thin client runs on client-server architecture and can be implemented with major existing VDI protocols to deliver the best user computing experience for virtual desktop solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191015005364/en/
Easy deployment and maintenance to optimize user experience
The TC238 AiO thin client designed with Intel® Smart Display Module (SDM-Large) featuring open pluggable, flexible integration, easy deployment and maintenance design to reduce total cost of ownership.
Energy-efficient and high performance for End user computing
Powered by high performance and power efficient Intel® Braswell x5-E8000 quad core processors, the TC238 AiO thin client supports DDR3L-1600 memory, storage options including mSATA SSD and on-board eMMC storages as manufacturing optional. The I/O connectors include two USB3.2 Gen 1 ports, two USB 2.0 ports, one DisplayPort, one DVI, audio ports as well as networking ability with a M.2 interface for WiFi and Bluetooth functionality.
High-density viewing and space-saving benefits
Featuring ultra-slim enclosure, the TC238 AiO thin client supports 23.8” full HD display and anti-glare panel for comfortable reading. Powered by one wire, it offers streamline and space-saving benefits for operations. In additions, it supports 4K display output to give users a rich, high-density viewing on external monitor.
Enhanced System Security & Virtual Desktop solutions
The TC238 thin client supports Trusted Platform Module (TPM) by manufacturing optional for secure data protection. Moreover, it supports all mainstream virtual desktop protocols including Microsoft RDP/ RemoteFX/WVD, Citrix HDX, and VMware Horizon View to ensure high availability and seamless communication with other applications.
The AiO TC238 thin client features highlight:
- Power-efficient Intel® Braswell x5-E8000 Quad Core Processor with fanless design
- Ultra-slim enclosure with open pluggable Intel® Smart Display Module (SDM-Large)
- Stylish 23.8” Full HD display with LED backlight
- Support up to 4K resolution for external display
- Able to rotate screen to upright position with optional stand
- Adjustable display swivel and tilt angle
- Support two USB 3.2 Gen 1, two USB 2.0, Giga LAN
- Support VESA mount for various mounting solutions
- Support Kensington lock
- Optional Wi-Fi module (M.2 2230 E Key Socket)
- Factory option for eMMC and TPM
The Clientron AiO Thin Client TC238 is available now. For more product details, please contact Clientron sales or visit our website www.clientron.com
About Clientron
Clientron is dedicated to be the professional thin client, POS, Automotive Electronics and embedded computing ODM provider for over 15 years. With providing Design, Manufacturing and Service support abilities for embedded computing, Clientron is your best embedded solution partner to empower more efficiency and safety for your e-World. Visit us at www.clientron.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20191015005364/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom